Iterum Therapeutics Launches New Antibiotic ORLYNVAH

Iterum Therapeutics ( (ITRM) ) has issued an update.

On August 20, 2025, Iterum Therapeutics announced the U.S. commercial launch of ORLYNVAH™, an FDA-approved oral antibiotic for adult women with uncomplicated urinary tract infections caused by specific bacteria with limited treatment options. This marks the first new branded product for uUTIs in over 25 years, addressing a critical need as antibiotic resistance rises, potentially reducing healthcare costs and improving patient outcomes.

The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.

Spark’s Take on ITRM Stock

According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.

Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.

To see Spark’s full report on ITRM stock, click here.

More about Iterum Therapeutics

Iterum Therapeutics plc is a pharmaceutical company focused on developing next-generation oral and IV antibiotics to combat multi-drug resistant pathogens. The company is advancing its novel penem anti-infective compound, sulopenem, which has shown potent activity against various resistant bacteria. Iterum has received FDA approval for ORLYNVAH™, an oral sulopenem for treating uncomplicated urinary tract infections in adult women.

Average Trading Volume: 750,071

Technical Sentiment Signal: Sell

Current Market Cap: $38.85M

Find detailed analytics on ITRM stock on TipRanks’ Stock Analysis page.